Tempest Therapeutics Inc
NASDAQ:TPST
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inspired PLC
LSE:INSE
|
UK |
|
MGX Minerals Inc
OTC:MGXMF
|
CA |
|
A
|
Asia Media Group Bhd
KLSE:AMEDIA
|
MY |
|
Whitecap Resources Inc
TSX:WCP
|
CA |
|
Gozco Plantations Tbk PT
IDX:GZCO
|
ID |
|
C
|
Caswell Inc
TWSE:6416
|
TW |
|
S
|
Suria Capital Holdings Bhd
KLSE:SURIA
|
MY |
|
Chengdu Xinzhu Road&Bridge Machinery Co Ltd
SZSE:002480
|
CN |
|
R
|
Renco Holdings Group Ltd
HKEX:2323
|
HK |
|
B
|
BDH Industries Ltd
BSE:524828
|
IN |
|
Currency Exchange International Corp
TSX:CXI
|
US |
|
Move Logistics Group Ltd
NZX:MOV
|
NZ |
|
Captii Ltd
SGX:AWV
|
SG |
|
Southern Packaging Group Ltd
SGX:BQP
|
SG |
|
EPI (Holdings) Ltd
HKEX:689
|
HK |
|
Les Hotels Baverez SA
PAR:ALLHB
|
FR |
|
Cheniere Energy Inc
NYSE:LNG
|
US |
|
Star Flyer Inc
TSE:9206
|
JP |
|
Kozosushi Co Ltd
TSE:9973
|
JP |
|
China General Plastics Corp
TWSE:1305
|
TW |
|
Rumo SA
BOVESPA:RAIL3
|
BR |
|
G
|
Goyal Aluminiums Ltd
NSE:GOYALALUM
|
IN |
|
Shake Shack Inc
NYSE:SHAK
|
US |
|
Inesa Intelligent Tech Inc
SSE:600602
|
CN |
Tempest Therapeutics Inc
Total Receivables
Tempest Therapeutics Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tempest Therapeutics Inc
NASDAQ:TPST
|
Total Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Receivables
$12.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Receivables
$4.9B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Receivables
$9.6B
|
CAGR 3-Years
20%
|
CAGR 5-Years
16%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Receivables
$2.1B
|
CAGR 3-Years
12%
|
CAGR 5-Years
18%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Receivables
$5.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Tempest Therapeutics Inc
Glance View
Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 17 full-time employees. The company went IPO on 2012-10-04. The firm is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company’s two clinical programs include TPST-1495 and TPST-1120. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor. TPST-1120 is in Phase I and II trials in solid tumors, including a global randomized Phase Ib/II trial in combination with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). TPST-1495, is a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is in a Phase I monotherapy and combination trial in solid tumors.
